Prometheus Research appoints vp of sales

Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.

Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.

Harker takes responsibility for developing and managing sales for the company's Research Informatics biomedical software services and new HTSQL database software for industry.

Prior to joining Prometheus, Harker held a variety of sales roles, most recently as managing director for BondDesk, a provider of software and services for fixed income trading.






You may also like

Finance

European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health

From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
You need to be a subscriber to read this article.
Click here to find out more.
Finance

From pilots to production: what 2026 could mean for pharma

This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the market in 2026
Digital

Beyond the portal: building the digital foundations for global CGT delivery

As 2025 unfolds and planning for 2026 gathers momentum, manufacturers face a landscape in which supply chain uncertainty, sustainability demands and digital transformation are reshaping priorities
Digital

Pharma in 2025–2026: AI, China and the new era of drug development

In 2025, the pace of change throughout chemical and pharmaceutical manufacturing is accelerating, creating a complex mix of emerging opportunities and structural challenges that will define the year ahead
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Finance

Symbiosis begins commercial manufacturing at new FDA-inspected facility

Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill-finish contract manufacturing organisation (CMO), has manufactured its first 10,000-vial batch at the company’s new facility in Stirling, UK
Manufacturing

ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies

Acquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three
Subscribe now